A Case Report of Primary Breast Angiosarcoma: Clinical Presentation and Outcome After Adjuvant Radiotherapy

Özgür Altmışdörtoğlu¹, Mustafa Şehsuvar Gökgöz¹, Ulviye Yalçınkaya¹, Meltem Nalca Andrieu¹
¹Department of Radiation Oncology, Near East University School of Medicine, Nicosia, Turkish Republic of Northern Cyprus
²Department of General Surgery, Uludağ University School of Medicine, Bursa, Turkey
³Department of Pathology, Uludağ University School of Medicine, Bursa, Turkey

ABSTRACT
Angiosarcomas of the breast are infrequent subtypes of sarcoma that are often diagnosed after radiation therapy for primary breast cancer. Primary angiosarcomas (PAS) are rare tumors that constitute 0.04% of all malignant breast tumors. We report a case of a 40-year-old woman with a lump in the right breast and diagnosed as angiosarcoma by pathological evaluation. She underwent simple mastectomy followed by adjuvant radiation. She is alive and disease-free for 66 months although tumor size was large and one surgical margin was tumor positive. Breast angiosarcoma is often in advanced stage at diagnosis and tends to recur locally. Although surgical methods constitute the primary treatment, we believe that a multidisciplinary treatment strategy should be used in high-risk patients with large primary tumors and tumor positive margins.

Keywords: Breast, primary angiosarcoma, radiotherapy, surgery

Introduction

Angiosarcoma (AS) is an aggressive tumor with differentiation to the endothelium of blood or lymphatic vessels. The tumor may arise from connective tissues in any anatomical region, including the scalp, the breast and the extremities and may spread over the overlying skin (1). They compose 1% of all sarcomas and the frequency is 0.0005–0.05% of all malignant neoplasms of the breast (2). Breast angiosarcomas may be classified as primary or secondary angiosarcoma. Primary angiosarcoma is a first-time developing tumor, while secondary angiosarcoma develops as a result of former breast cancer treatment (e.g., used postoperative radiotherapy and/or long-lasting lymphedema after treatment for breast cancer known as Stewart-Treves syndrome) (3). As primary angiosarcoma of the breast (PAB) is an uncommon malignancy, there are no randomized trials to lead clinical decision-making in the management of angiosarcoma.

Case Presentation

A 40-year-old premenopausal patient who had a breast reduction operation approximately 3 years before admitted to the general surgery department in 2013 with complaint of palpable mass in the right breast which had a fast growing. There was no other remarkable feature in the patient’s medical history. The mass was localized deeply without skin coloration change or signs of mastitis. She had no chronic illness or radiotherapy history and no family history of breast cancer. An excisional biopsy was performed on 07.06.2013 and revealed sarcomatous changes. The patient underwent a simple mastectomy followed by adjuvant radiotherapy. She is alive and disease-free for 66 months although tumor size was large and one surgical margin was tumor positive. Breast angiosarcoma is often in advanced stage at diagnosis and tends to recur locally. Although surgical methods constitute the primary treatment, we believe that a multidisciplinary treatment strategy should be used in high-risk patients with large primary tumors and tumor positive margins.
Physical examination every 3 months and thoracic computed tomography every 6 months for the first 3 years and then once a year were performed during follow-up. Throughout the period of follow-up until February 2019, the patient had no evidence of local or distant metastasis. As the patient was living far away from the treatment center, follow-up procedures are evaluated by the photographs of the reports and informed consent is taken verbally by telephone before she sent it by post.

Discussion and Conclusion

PAS typically appears in women 30–50 years of age with no former history of cancer or recognizable risk factors. It composes less than 0.04% of malignant tumors and typically appears in the parenchyma of the breast with uncommon skin involvement. Contrarily, secondary AS presents in elder women (median age 67-71 years) following a median of 10.5 years after radiotherapy for breast cancer. The median latent period to appearance after irradiation in seven series ranges from 5 to 10 years (4).

Key Points

- As primary angiosarcomas of the breast are very rare, it is not possible to use randomized trials to find out the standard treatment.
- The management of PAS must be carried by a multidisciplinary team.
- High risk PAS patients may survive long with aggressive treatments including adjuvant radiotherapy.
Angiosarcoma may have a hidden clinical start, displaying frequently as a painless separate palpable mass that grows quickly. Nearly 2% of patients may exist with diffuse expansion of the breast. On the other hand, a bluish red discoloration of the overlying skin may be present (5). The age of our patient and the clinical symptoms of the disease were compatible with PAS.

Diagnosis may be difficult because of the absence of typical radiologic features on the mammogram or ultrasonogram. A Magnetic Resonance Imaging (MRI) of the breast is frequently helpful in specifying a tumor of vascular nature with malignant kinetic features. An exact preoperative diagnosis can be obtained with fine-needle aspiration cytology or a core needle biopsy (6). Chen et al. (7) declared that the false negative incidence of percutaneous biopsy was 37%. Large-core biopsies might enable the accurate diagnosis as they ensure a larger sample, but such a macro biopsy is frequently hard to apply because of the vascular nature of these tumors. Surgical resection and microscopic examination of adequate sampling of the tumor are often necessary to give a final diagnosis which was the case for our patient (Figures 1 and 2) (5).

The histologic features of angiosarcoma of the breast are classified into grades I, II and III. In addition, immunohistochemistry can be useful to identify the clone JC/70A (CD31, the human hematopoietic progenitor cell antigen), endothelial indicator of vascular proliferation. Other specific markers for this kind of lesions are Factor VIII, and Friend leukemia integration 1 transcription factor (FLI1) (8). Angiogenesis, considered to be strongly affected by vascular endothelial growth factor (VEGF), is very important in the pathogenesis of these tumors. The histologic grade of primary angiosarcoma of the breast plays an important role in the estimation of outcomes, it is the most important prognostic indicator in cases of PAB (9). Concerning the correlation between high proliferation index and poor prognosis in a Grade II tumor in a study, Ozluk et al. (10) proposed that Ki-67 proliferation index should be used to predict nonhigh-grade tumors with unfavorable outcome. Low proliferation index of two grade I tumors in their study also supports the theory of relationship between Ki-67 antigen and aggressiveness of PAB.

Kaklamanos et al. (6) found that tumor size, grade, and margin status are the most important prognostic factors for survival. They remarked adjuvant multimodality therapy may improve the outcome in selected patients with breast angiosarcoma. Thirty-two PAS of the breast were reported by M.D. Anderson Cancer Center, 9 had received neoadjuvant or adjuvant radiotherapy combined with surgery and chemotherapy and overall survival of all was 59%. Tumor recurrence was the only significant adverse prognostic factor for OS in multivariate analysis (11).

As angiosarcomas of the breast are very rare, there is no accepted standard treatment. Surgery (either mastectomy or wide excision) remains the basis of the treatment. Due to the highly aggressive course of the disease and its tendency to have local recurrence and distant metastasis, other treatment methods such as chemotherapy or radiotherapy should be used, under the inspection of a multidisciplinary team (3). The declared proportions of advanced/metastatic disease at presentation changes from 16 to 44%, and the overall disease-specific survival

The histologic features of angiosarcoma of the breast are classified into grades I, II and III. In addition, immunohistochemistry can be useful to identify the clone JC/70A (CD31, the human hematopoietic progenitor cell antigen), endothelial indicator of vascular proliferation. Other specific markers for this kind of lesions are Factor VIII, and Friend leukemia integration 1 transcription factor (FLI1) (8). Angiogenesis, considered to be strongly affected by vascular endothelial growth factor (VEGF), is very important in the pathogenesis of these tumors. The histologic grade of primary angiosarcoma of the breast plays an important role in the estimation of outcomes, it is the most important prognostic indicator in cases of PAB (9).

Kaklamanos et al. (6) found that tumor size, grade, and margin status are the most important prognostic factors for survival. They remarked adjuvant multimodality therapy may improve the outcome in selected patients with breast angiosarcoma. Thirty-two PAS of the breast were reported by M.D. Anderson Cancer Center, 9 had received neoadjuvant or adjuvant radiotherapy combined with surgery and chemotherapy and overall survival of all was 59%. Tumor recurrence was the only significant adverse prognostic factor for OS in multivariate analysis (11).

As angiosarcomas of the breast are very rare, there is no accepted standard treatment. Surgery (either mastectomy or wide excision) remains the basis of the treatment. Due to the highly aggressive course of the disease and its tendency to have local recurrence and distant metastasis, other treatment methods such as chemotherapy or radiotherapy should be used, under the inspection of a multidisciplinary team (3). The declared proportions of advanced/metastatic disease at presentation changes from 16 to 44%, and the overall disease-specific survival

The histologic features of angiosarcoma of the breast are classified into grades I, II and III. In addition, immunohistochemistry can be useful to identify the clone JC/70A (CD31, the human hematopoietic progenitor cell antigen), endothelial indicator of vascular proliferation. Other specific markers for this kind of lesions are Factor VIII, and Friend leukemia integration 1 transcription factor (FLI1) (8). Angiogenesis, considered to be strongly affected by vascular endothelial growth factor (VEGF), is very important in the pathogenesis of these tumors. The histologic grade of primary angiosarcoma of the breast plays an important role in the estimation of outcomes, it is the most important prognostic indicator in cases of PAB (9).

Kaklamanos et al. (6) found that tumor size, grade, and margin status are the most important prognostic factors for survival. They remarked adjuvant multimodality therapy may improve the outcome in selected patients with breast angiosarcoma. Thirty-two PAS of the breast were reported by M.D. Anderson Cancer Center, 9 had received neoadjuvant or adjuvant radiotherapy combined with surgery and chemotherapy and overall survival of all was 59%. Tumor recurrence was the only significant adverse prognostic factor for OS in multivariate analysis (11).

As angiosarcomas of the breast are very rare, there is no accepted standard treatment. Surgery (either mastectomy or wide excision) remains the basis of the treatment. Due to the highly aggressive course of the disease and its tendency to have local recurrence and distant metastasis, other treatment methods such as chemotherapy or radiotherapy should be used, under the inspection of a multidisciplinary team (3). The declared proportions of advanced/metastatic disease at presentation changes from 16 to 44%, and the overall disease-specific survival

The histologic features of angiosarcoma of the breast are classified into grades I, II and III. In addition, immunohistochemistry can be useful to identify the clone JC/70A (CD31, the human hematopoietic progenitor cell antigen), endothelial indicator of vascular proliferation. Other specific markers for this kind of lesions are Factor VIII, and Friend leukemia integration 1 transcription factor (FLI1) (8). Angiogenesis, considered to be strongly affected by vascular endothelial growth factor (VEGF), is very important in the pathogenesis of these tumors. The histologic grade of primary angiosarcoma of the breast plays an important role in the estimation of outcomes, it is the most important prognostic indicator in cases of PAB (9).

Kaklamanos et al. (6) found that tumor size, grade, and margin status are the most important prognostic factors for survival. They remarked adjuvant multimodality therapy may improve the outcome in selected patients with breast angiosarcoma. Thirty-two PAS of the breast were reported by M.D. Anderson Cancer Center, 9 had received neoadjuvant or adjuvant radiotherapy combined with surgery and chemotherapy and overall survival of all was 59%. Tumor recurrence was the only significant adverse prognostic factor for OS in multivariate analysis (11).

As angiosarcomas of the breast are very rare, there is no accepted standard treatment. Surgery (either mastectomy or wide excision) remains the basis of the treatment. Due to the highly aggressive course of the disease and its tendency to have local recurrence and distant metastasis, other treatment methods such as chemotherapy or radiotherapy should be used, under the inspection of a multidisciplinary team (3). The declared proportions of advanced/metastatic disease at presentation changes from 16 to 44%, and the overall disease-specific survival

The histologic features of angiosarcoma of the breast are classified into grades I, II and III. In addition, immunohistochemistry can be useful to identify the clone JC/70A (CD31, the human hematopoietic progenitor cell antigen), endothelial indicator of vascular proliferation. Other specific markers for this kind of lesions are Factor VIII, and Friend leukemia integration 1 transcription factor (FLI1) (8). Angiogenesis, considered to be strongly affected by vascular endothelial growth factor (VEGF), is very important in the pathogenesis of these tumors. The histologic grade of primary angiosarcoma of the breast plays an important role in the estimation of outcomes, it is the most important prognostic indicator in cases of PAB (9).

Kaklamanos et al. (6) found that tumor size, grade, and margin status are the most important prognostic factors for survival. They remarked adjuvant multimodality therapy may improve the outcome in selected patients with breast angiosarcoma. Thirty-two PAS of the breast were reported by M.D. Anderson Cancer Center, 9 had received neoadjuvant or adjuvant radiotherapy combined with surgery and chemotherapy and overall survival of all was 59%. Tumor recurrence was the only significant adverse prognostic factor for OS in multivariate analysis (11).

As angiosarcomas of the breast are very rare, there is no accepted standard treatment. Surgery (either mastectomy or wide excision) remains the basis of the treatment. Due to the highly aggressive course of the disease and its tendency to have local recurrence and distant metastasis, other treatment methods such as chemotherapy or radiotherapy should be used, under the inspection of a multidisciplinary team (3). The declared proportions of advanced/metastatic disease at presentation changes from 16 to 44%, and the overall disease-specific survival

<table>
<thead>
<tr>
<th>Author</th>
<th>Number of cases PAS/ Total</th>
<th>RT (+)</th>
<th>CT (+)</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kunkiel et al. (3)</td>
<td>11/11</td>
<td>5/11</td>
<td>3/11</td>
<td>10 patients (91%) relapsed with local or distant recurrence.</td>
</tr>
<tr>
<td>Vorburger et al. (11)</td>
<td>32/55</td>
<td>37/55</td>
<td>9/32</td>
<td>DFS and OS for all: median 2.26 and 2.96 years, DFS and OS for PAS: 3-year 58% and 80%</td>
</tr>
<tr>
<td>Rosen et al. (12)</td>
<td>?/63 (56 AS)</td>
<td>15/63</td>
<td>31/63</td>
<td>5-year OS: grade I 76%, grade II 70%, grade III 15%.</td>
</tr>
<tr>
<td>Molitor et al. (16)</td>
<td>8/8</td>
<td>3/8</td>
<td>0/8</td>
<td>Median DFS was 9 months, OS was 13 months</td>
</tr>
<tr>
<td>Scow et al. (17)</td>
<td>27/27</td>
<td>11/27</td>
<td>13/27</td>
<td>5-year OS 46%</td>
</tr>
<tr>
<td>Sher et al. (18)</td>
<td>56/69</td>
<td>46/69</td>
<td>30/69</td>
<td>RFS and OS: median 37 and 100 months; 5-year 44% and 61%; RT (+) / RT (+) 33%/47% and 50%/65%</td>
</tr>
<tr>
<td>Nacimento et al. (19)</td>
<td>47/49</td>
<td>12/49</td>
<td>11/49</td>
<td>Median RFS was 2.1 years, OS was 5.8 years</td>
</tr>
<tr>
<td>Luini et al. (20)</td>
<td>9/16</td>
<td>3/16</td>
<td>5/16</td>
<td>DFS and OS for PAS: 5-year 56% and 78%</td>
</tr>
</tbody>
</table>

AS: angiosarcoma; CT: chemotherapy; DFS: disease free survival; OS: overall survival; PAS: primary angiosarcoma; RFS: recurrence free survival; RT: radiotherapy
is reported as rounded 30–40% in actual series (1). With respect to Rosen’s study, the 5 years disease free survival rate for low grade tumors can be as high as 76% and up to 70% for intermediate grade tumors. However, 5 years survival rate for high grade tumors is about 15% (12). Gross tumor resection with tumor negative resection margins is appraised as the preferred treatment whenever possible for localized disease. Nevertheless, some authors discuss that with the application of multimodal local treatment in scalp and face angiosarcomas, microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed (R0 resection) does not give any advantage over complete tumor resection (debulking). This situation may be related with fewer complications and the tolerance of adjuvant therapies may be better (13). As local recurrence incidences are comparatively high even after R0 resection, adjuvant radiotherapy is generally suggested, and it has been correlated with better survival in some series (14, 15). Molitor et al. (16) published the outcome of 8 cases of primary breast angiosarcoma which were treated between 1954 and 1995. Only 3 had received adjuvant radiotherapy after mastectomy, median DFS and OS were 9 and 13 months consecutively. Scow et al. (17) reported twenty-seven cases of PAS of breast treated in Mayo Clinic. Median tumor size was 7.0 cm and 33% of tumors were high grade. All patients underwent mastectomy, eight of them received chemotherapy and radiotherapy, five patients received chemotherapy only, and three patients received radiation only. Five-year survival was 46%. Sher et al. (18) reported recurrence-free survival of 47% and 44% at 5 and 10 years in 68% of 69 patients irradiated compared with the patients who did not receive radiotherapy (33% and 25% at 5 and 10 years respectively). This rate indicates that recurrence free survival is higher with adjuvant radiotherapy. When surgical resection is contraindicated or not possible, chemotherapy is taken into consideration with the aim of either palliation or downsizing the tumor to be suitable for resection. Even though there is no fixed standard systemic therapy, paclitaxel and doxorubicin are among the most active agents. Targeted therapies, especially new agents against angiogenesis are being explored (1). In one retrospective analysis, Buehler et al. (1) reviewed demographic, tumor and treatment characteristics of 81 patients with angiosarcomas of different sites in the body (5/81 was PAS of breast) were evaluated at the University of Wisconsin Hospital and Clinic. By univariate analysis, significant unfavorable predictors of survival included metastases at presentation, visceral/deep soft tissue tumor location, tumor size >5 cm, tumor necrosis and the lack of surgical excision. A tendency toward protracted survival was seen with radiation therapy and for chemotherapy in patients with metastases. A summary of the outcomes of primary breast angiosarcoma in the published literature is shown in Table 1 (3, 11, 12, 16-20). Our patient with PAS is alive and disease-free for 66 months after mastectomy + adjuvant radiotherapy. Although tumor size was large and one surgical margin was tumor positive, the outcome is good because of the low grade and aggressive treatment. The management of PAS with multidisciplinary care, including plastic surgeons, medical, radiation and surgical oncologists is important to facilitate the complex decision making and to allow for the multimodality therapies necessary in the treatment of this aggressive malignancy.


